Related Experiment Videos
Thrombosis in cancer patients
1Department of Internal Medicine, Academic Hospital Maastricht, The Netherlands.
Summary
Venous thromboembolism (VTE) is a frequent complication in cancer patients, often linked to malignancy. Activated blood coagulation in cancer patients can be targeted by low-molecular weight heparins for VTE prevention and treatment.
Area of Science:
- Oncology
- Hematology
- Thrombosis
Background:
- Venous thromboembolism (VTE) is a common complication in cancer patients, frequently presenting as an initial sign of malignancy.
- Cancer promotes blood coagulation activation through tumor cell expression of tissue factor and cancer procoagulant, affecting clotting factors VII and X.
- Tumor-derived cytokines further activate coagulation on monocytes, platelets, and endothelial cells, exacerbating clinical VTE.
Purpose of the Study:
- To review the role of activated coagulation in cancer-associated VTE.
- To discuss the efficacy and safety of low-molecular weight heparins in managing VTE in cancer patients.
- To explore the implications of coagulation activation in supporting tumor growth and angiogenesis for novel cancer treatment strategies.
Main Methods:
- Literature review of studies on VTE in cancer patients.
- Analysis of the mechanisms of cancer-induced coagulation activation.
- Evaluation of therapeutic strategies for VTE in oncology.
Main Results:
- Cancer significantly activates the blood coagulation system, increasing VTE risk.
- Low-molecular weight heparins demonstrate effectiveness and safety in preventing and treating VTE in cancer patients.
- Activated coagulation pathways are implicated in promoting tumor growth and angiogenesis.
Conclusions:
- VTE is a critical complication in cancer management, driven by tumor-induced coagulation.
- Low-molecular weight heparins are a cornerstone therapy for VTE in this population.
- Targeting coagulation pathways presents a promising avenue for future cancer therapies.